Long-acting hypoglycemic drugs mainly include long-acting insulin and long-acting oral hypoglycemic drugs, and most of the long-acting hypoglycemic drugs will not harm the liver and kidney function. Most of the oral hypoglycemic drugs currently available on the market, mainly metformin extended-release tablets, gliclazide extended-release tablets, ligustine, etc., as long as the standardized use of hypoglycemic drugs generally will not harm the liver and kidney function; oral hypoglycemic drugs that can seriously damage the liver and kidney function are currently prohibited. Long-acting insulin mainly includes Degu insulin, Dieter’s insulin, Glycine insulin, etc. Under the guidance of doctors, the standardized use of medication generally will not have an impact on the liver and kidney function, but also be able to play a role in lowering the blood glucose; however, the injection of insulin treatment may have hypoglycemia, allergic reactions, subcutaneous fat atrophy and hardness, and so on. Patients who need to be treated with long-acting hypoglycemic drugs should be treated under the guidance of a doctor.